Buprenorphine: "Field trials" of a new drug

Qualitative Health Research

Volumn 11, Issue 1, 2001, Pages 69-84

  Agar, Michael ^a   Bourgois, Philippe ^b   French, John ^c   Murdoch, Owen ^a,d,e  

^a School of Medicine ^*

^b UNIVERSITY OF SAN FRANCISCO   (United States)

^c New Jersey Department of Health   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e HIV prevention Projects   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NARCOTIC ANTAGONIST; STREET DRUG;

ARTICLE; BIBLIOMETRICS; EVALUATION; FORECASTING; HUMAN; OPIATE ADDICTION; PROBABILITY; UNITED STATES;

BIBLIOMETRICS; BUPRENORPHINE; FORECASTING; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PROBABILITY; STREET DRUGS; UNITED STATES;

EID: 0035218839     PISSN: 10497323     EISSN: None     Source Type: Journal    
DOI: 10.1177/104973201129118948     Document Type: Article

References (56)

1. Agar, M. (1977). Going through the changes: Methadone in New York. Human Organization, 36, 291-295.
2. Agar, M., & Stephens, R. (1975). The methadone street scene: The addict's view. Psychiatry, 38, 381-387.
3. Ahmed, S. K., & Ara, N. (1995). Patterns and trends of buprenorphine abuse: An ethnographic study. Report prepared for the Community Epidemiology Work Group, National Institute of Drug Abuse, Washington, DC. Manuscript submitted for publication.
4. Arditti, J., Bourdon, J. H., Jean, P., Landi, H., Nasset, D., Jouglard, J., & Thirion, X. (1992). Buprenorphine abuse in a group of 50 drug-use abusers admitted to Marseille hospital. Thérapie, 47, 561-562.
5. Bickel, W. K., Amass, L., Higgins, S. T., Badger, G., & Esch, R. A. (1997). Effects of adding behavioral treatment to opiate detoxification with buprenorphine. Journal of Consulting and Clinical Psychology, 65(5), 803-810.
6. Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988). Clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics, 43, 72-78.
7. Bourgois, P. (2000). Disciplining addictions: The bio-politics of methadone and heroin in the United States. Culture, Medicine and Psychiatry, 24(2), 165-195.
8. Brown, E. (1993). Investigations of the neurobiological and behavioral actions of cocaine. Unpublished doctoral dissertation, University of British Columbia.
9. Cohen, J., Schamroth, A., Nazareth, I., Johnson, M., Thomson, D., & Graham, S. (1992). Problem drug use in a central London general practice. British Medical Journal, 304, 1158-1160.
10. Eder, H., Fischer, G., Gombas, W., Jagsch, R., Stuhlinger, G., & Kasper, S. (1998). Comparison of buprenorphine and methadone maintenance in opiate addicts. European Addiction Research, 4, 3-7.
11. Fischer, G., Gombas, W., Eder, H., Jagsch, R., Peternell, A., Stuhlinger, G., Pezawas, L., Aschauer, H. N., & Kasper, S. (1999). Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction, 94, 1337-1347.
12. Foltin, R. W., & Fischman, M. W. (1996). Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. Journal of Pharmacology and Experimental Therapeutics, 278, 153-164.
13. Fudala, P. J., Jaffe, J. H., Dax, E. M., & Johnson, R. E. (1990). Use of buprenorphine in the treatment of opioid addiction: Part 2. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clinical Pharmacology and Therapeutics, 47, 525-534.
14. Griffin, S., Peters, A., & Reid, M. (1993). Drug misusers in Lothian: Changes in injecting habits. British Medical Journal, 306(6879), 693.
15. Gruer, L., Cameron, J., & Elliott, L. (1993). Building a city wide service for exchanging needles and syringes. British Medical Journal, 306(6889), 1394.
16. Hakkarainen, P., & Hoikkala, T. (1992). Temgesic: Gullible doctors, drug addicts in disguise. Nordisk Alkohol Tidskrift, 9(5), 261-274.
17. Holloway, M. (1991). Rx for addiction. Scientific American, 264(3), 94.
18. Jasinski, D. R., Fudala, P. J., & Johnson, R. E. (1989). Sublingual versus subcutaneous buprenorphine in opiate abusers. Clinical Pharmacology and Therapeutics, 45, 513-519.
19. Jasinski, D. R., Pevnick, J. S., & Griffith, J. D. (1978). Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry, 35, 501-516.
20. Johnson, R. E., Cone, E. J., Henningfield, J. E., & Fudala, P. J. (1989). Use of buprenorphine in the treatment of opiate addiction: Part 1. Physiologic and behavioral effects during a rapid dose induction. Clinical Pharmacology and Therapeutics, 46, 335-343.
21. Johnson, R. E., Jaffe, J. H., & Fudala, P. J. (1992). Controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association, 267, 2750-2755.
22. Kempfer, J. (1998a). De l'Ortenal à l'Artane: Les detournements de médicaments et leurs consequences [From Ortenal to Artane: The consequences of the black market in medicines]. Interdépendance Journal de SOS Drogues International, 31, no pagination.
23. Kempfer, J. (1998b). La vie à Paris avec drogues mais sans toit [Living in Paris with drugs, but without shelter]. SWAPS, 7, 2-4.
24. Kempfer, J. (1998/1999). Subutex: Au commencement était le Temgesic et celui-ci était injectable [Subutex: In the beginning there was Temgesic and it was injectable]. SWAPS, 10, 6-7.
25. Kempfer, J. (2000). "Des produits utilisés par les usagers de drogues du centre de Paris [Some products consumed by drug users in the center of Paris]. Excerpted in 1998 report to the AUDVIH (Aide aux Usagers de Drogues confrontés au VIH). Paris: Association AIDES Ile de France.
26. Kumar, M. S., Mandell, W., Shakuntala, S., & Daniels, D. (1995, June). Buprenorphine dependence among injecting drug users in Madras City, India. Paper presented at the annual meeting of College on the Problems of Drug Dependence, Scottsdale, AZ.
27. Lebedevs, T. (1985). Buprenorphine abuse. Pharmaceutical Journal, 235, 641.
28. Lefort, C. (1998). Le crack: Le connaitre pour mieux prévenir [Crack: Understanding it to improve prevention]. Réseau des hautes Etudes des pratiques socialisés: Groupement des Colleges Cooperatifs.
29. Leinwand, D. (2000, May 30). Heroin's new fix and why it matters to you. USA Today, p. 1.
30. Lert, F., Bégaud, B., Fuhrer, R., Henrion, R., Lalande, M., Ledit, D., Lovell, A., Obadia, Y., Parquet, P., Puech, A., Tassin, J. P., & Vittecoq, D. (1998). Evaluer la mise à disposition du Subutex pour la prise en charge des usagers de drogue [An evaluation of the prescription of Subutex for the treatment of drug users]. Paris: INSERM.
31. Lovell, A. (in press). Ordonner les risques [Prescribing risk]. In D. Fassin & J. P. Dozon (Eds.), Anthropologies et Santé Publique.
32. Mello, N. K., Mendelson, J. H., & Kuehnle, J. C. (1982). Buprenorphine effects on human heroin self administration: Operant analysis. Journal of Pharmacology and Experimental Therapeutics, 223, 30-39.
33. Mendelson, J., Jones, R. T., Welm, S., Brown, J., & Batki, S. L. (1997). Buprenorphine and naloxone interactions in methadone maintenance patients. Biological Psychiatry, 41, 1095-1101.
34. Michman, R. D. (1994). Marketing to changing consumer markets: Environmental scanning. New York: Praeger.
35. Nath, R. P. (1999). Buprenorphine and naloxone combinations: The effects of three dose rations in morphine stabilized opiate-dependent volunteers. Psychopharmacology, 141, 37-46.
36. Navaratnam, V. (1995). The Asian multicity epidemiology work group: 1994 update. Proceedings of the Community Epidemiology Work Group Chicago Meeting (pp. 313-319). Rockville, MD: National Institute on Drug Abuse.
37. O'Connor, P. G., Oliveto, A. H., Shi, J. M., Triffleman, E., Carroll, K. M., Kosten, T. R., & Rounsaville, B. J. (1996). A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. American Journal of Drug and Alcohol Abuse, 22, 523-531.
38. O'Connor, P. G., Oliveto, A. H., Shi, J. M., Triffleman, E. G., Carroll, K. M., Kosten, T. R., Rounsaville, B. J., Pakes, J. A., & Schottenfeld, R. S. (1998). A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine, 105, 100-105.
39. Petry, N. M., Bickel, W. K., & Badger, G. J. (1999). A comparison of four buprenorphine dosing regimes in the treatment of opiod dependence. Clinical Pharmacology and Therapeutics, 66, 306-314.
40. Pickworth, W. B., Johnson, R. E., Holicky, B. A., & Cone, E. J. (1993). Subjective and physiologic effects of intravenous buprenorphine in humans. Clinical Pharmacology and Therapeutics, 53, 570-576.
41. Preble, E., & Miller, T. (1977). Methadone, wine, and welfare. In R. Weppner (Ed.), Street ethnography (pp. 229-248). Beverly Hills, CA: Sage.
42. Quigley, A. J., Bredemeyer, D. E., & Seow, S. S. (1984). Case of buprenorphine abuse. Medical Journal of Australia, 140, 425-426.
43. Resnick, R., & Falk, F. (1987). Buprenorphine: Pilot trials in borderline patients and opiate dependence - treatment of a common disorder? In L. S. Harris (Ed.), Problems of drug dependence (pp. 155-168). Washington, DC: National Institute on Drug Abuse Research.
44. Resnick, R., Galanter, M., Psycha, C., Cohen, A., Grandison, P., & Flood, N. (1992). Buprenorphine: An alternative to methadone for heroin dependence treatment. Psychopharmacology Bulletin, 28, 109-113.
45. Resnick, R., Resnick, E., & Galanter, M. (1991). Buprenorphine responders: A diagnostic subgroup of heroin addicts. Psychiatry, 14(4), 531-538.
46. Rosen, M. I., Pearsall, H. R., McDougle, C. J., Price, L. H., & Kosten, T. R. (1993). Effects of acute buprenorphine on responses to intranasal cocaine: Pilot study. American Journal of Drug and Alcohol Abuse, 19(4), 451-464.
47. San, L., Torrens, M., Castillo, C., Porta, M., & De La Torre, R. (1993). Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: Results from cross-sectional studies in 1988 and 1990. Addiction, 88(10), 1341-1349.
48. Schottenfeld, R. S., Pakes, J. R., & Kosten, T. R. (1998). Prognostic factors in buprenorphine versus methadone-maintained patients. Journal of Nervous and Mental Disorders, 186, 35-43.
49. Schottenfeld, R. S., Pakes, J. R., Oliveto, A., Ziedonis, D., & Kosten, T. R. (1997). Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry, 54, 713-720.
50. Seyer, D., Dif, C., Balthazard, G., & Sciortino, V. (1998). Maintenance treatment with high-dose buprenorphine: Are the recommendations being followed? Thérapie, 53, 349-354.
51. Sherden, W. A. (1998). The fortune sellers: The big business of buying and selling predictions. New York: John Wiley.
52. Stewart, M. J. (1991). Effect of scheduling of buprenorphine (temgesic) on drug abuse patterns in Glasgow. British Medical Journal, 302, 969.
53. Strang, J. (1991). Abuse of buprenorphine (temgesic) by snorting. British Medical Journal, 302, 969.
54. Tracqui, A., Kintz, P., & Ludes, B. (1998). Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. Journal of Analytic Toxicology, 22, 430-434.
55. Waldorf, M. M. (1992). Complexity: The emerging science at the edge of order and chaos. New York: Simon & Schuster.
56. Wodak, A. D. (1984). Buprenorphine: New wonder drug or new hazard? Medical Journal of Australia, 140, 389-390.